6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

August 17, 2009

Commission File Number 001-14956

BIOVAIL CORPORATION

(Translation of Registrant’s name into English)

7150 Mississauga Road, Mississauga, Ontario, CANADA, L5N 8M5

(Address of principal executive office and zip code)

Registrant’s telephone number, including area code: (905) 286-3000

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                        Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes o                        No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes o                        No x

Indicate by check mark whether by furnishing the information contained in this form the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g 3-2(b) under the Securities Exchange Act of 1934.

Yes o                        No x

BIOVAIL CORPORATION

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-92229 and 333-138697) of Biovail Corporation.

INDEX

Exhibit 99.1          News Release Dated August 17,  2009:   Biovail Comments on Ultram ® ER Court Ruling

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Biovail Corporation
Date:  August 17, 2009	By:	/ s / Jennifer Tindale
		Jennifer Tindale
		Vice President &
		Associate General Counsel

i

EX-99.1

Exhibit 99.1

CONTACT: Nelson F. Isabel

Vice-President, Investor Relations

& Corporate Communications

(905) 286-3000

For Immediate Release:

BIOVAIL COMMENTS ON ULTRAM® ER COURT RULING

TORONTO, Canada, August 17, 2009 – Biovail Corporation (NYSE, TSX: BVF) announced today that on August 14, 2009, in the United States District Court for the District of Delaware, Judge Kent A. Jordan issued an opinion in favour of Par Pharmaceuticals, Inc. (Par) in the patent-infringement litigation relating to Ultram® ER (tramadol hydrochloride extended-release tablets). Although Biovail is not a party to the action, the decision could have an effect on Biovail’s revenues relating to Ultram® ER.

The Court’s ruling, in conjunction with Par’s recent receipt of tentative approval from the U.S. Food and Drug Administration (FDA) for its 100mg and 200mg strength tablets, could allow Par to launch their generic formulation of those tablet strengths at any time. Biovail will be consulting with its partner, Pricara (a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.) to determine next steps. The decision as to whether or not to appeal the decision lies with Purdue Pharma LP, the patent holder.

Biovail recorded Ultram® ER revenues of $81.9 million in 2008, and $37.2 million in the first half of 2009.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company’s web site at www.biovail.com.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com.